Immunotherapy for head and neck cancer: where do we go from here?

被引：0
|
作者：
Ko, Eric C. [1 ]
Hanna, Glenn J. [2 ]
机构：
[1] Univ Massachusetts, UMass Mem Med Ctr, Chan Med Sch, Dept Radiat Oncol, 55 Lake Ave North, Worcester, MA 01655 USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Ctr Head & Neck Oncol, 450 Brookline Ave, Boston, MA 02215 USA
来源：
IMMUNOTHERAPY | 2023年
关键词：
cancer immunology; checkpoint inhibitors; head and neck squamous cell cancer; immunotherapy; radiotherapy; SQUAMOUS-CELL CARCINOMA; OPEN-LABEL; PEMBROLIZUMAB; CETUXIMAB; RECURRENT; CHEMOTHERAPY; MULTICENTER; NIVOLUMAB; CARE;
D O I：
10.2217/imt-2023-0191
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Immunotherapy for head and neck cancer shows promising new directions - and challenges ahead. What can we learn from recent trials to improve patient selection and optimize combination therapy?
引用
收藏
页码：1497 / 1500
页数：4
相关论文
共 50 条
  • [21] Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors
    Reyes-Gibby, Cielito C.
    Qdaisat, Aiham
    Ferrarotto, Renata
    Fadol, Anecita
    Bischof, Jason J.
    Coyne, Christopher J.
    Lipe, Demis N.
    Hanna, Ehab Y.
    Shete, Sanjay
    Abe, Jun-Ichi
    Yeung, Sai-Ching J.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (03): : 627 - 635
  • [22] Immunotherapy in Head and Neck Cancer Treatment Paradigms, Future Directions, and Questions
    Fishman, Danielle
    Choe, Jennifer
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 33 (04) : 605 - 615
  • [23] Platelet transfusions: where do we go from here?
    Kaufman, R. M.
    TRANSFUSION MEDICINE, 2016, 26 (01) : 5 - 7
  • [24] Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?
    Peng, Yan
    Yan, Hongxiang
    Mei, Wuxuan
    Zhang, Pengfei
    Zeng, Changchun
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (10) : 1378 - 1391
  • [25] Telemedicine Postpandemic Where Do We Go From Here?
    Green, Eric H.
    Aquino, Patrick J.
    Keitz, Sheri A.
    MEDICAL CARE, 2023, 61 (08) : 491 - 494
  • [26] Role of Immunotherapy in Head and Neck Cancer
    Ling, Diane C.
    Bakkenist, Chris J.
    Ferris, Robert L.
    Clump, David A.
    SEMINARS IN RADIATION ONCOLOGY, 2018, 28 (01) : 12 - 16
  • [27] Current Status and Future Aspects of Stereotactic Body Radiotherapy and Immunotherapy in the Management of Recurrent Head and Neck Cancer
    Ozyigit, Gokhan
    Sari, Sezin Yuce
    Yazici, Gozde
    Cengiz, Mustafa
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2019, 34 (04): : 313 - 320
  • [28] Proton Radiotherapy for Prostate Cancer: How Did We Get Here, and Where Do We Go From Here?
    Yu, James B.
    Efstathiou, Jason A.
    Bekelman, Justin E.
    ONCOLOGY-NEW YORK, 2013, 27 (12): : 1293 - 1294
  • [29] Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: A single-center experience
    Sari, Sezin Yuce
    Yilmaz, Melek Tugce
    Aktas, Burak Yasin
    Aksoy, Sercan
    Gullu, Ibrahim
    Cengiz, Mustafa
    Ozyigit, Gokhan
    Yazici, Gozde
    ORAL ONCOLOGY, 2022, 124
  • [30] Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective
    Cabezas-Camarero, Santiago
    Perez-Segura, Pedro
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 169
12345